To appreciate why this case has drawn attention, it helps to understand what angiosarcoma actually is. The disease arises from endothelial cells, the flat cells that line the interior surface of blood vessels and lymphatic channels. When these cells turn malignant, they proliferate into wildly disorganized networks of immature, blood-filled channels, solid sheets of atypical cells, or nodular masses that infiltrate surrounding tissue. Angiosarcoma is aggressive by nature, with an early tendency to metastasize to distant organs, and it accounts for only a small fraction of an already uncommon category of cancers. Sarcomas as a whole represent roughly one percent of adult malignancies, and angiosarcomas make up only about two percent of those, which places this tumor among the rarest cancers that oncologists ever confront.

Most cases of cutaneous angiosarcoma do not appear out of nowhere. The two dominant risk factors are chronic lymphedema, the persistent swelling that occurs when lymphatic drainage is blocked, and prior radiotherapy, which can damage vascular tissue in ways that promote malignant transformation years later. Beyond those, researchers have linked angiosarcoma to familial syndromes such as neurofibromatosis and Klippel-Trenaunay syndrome, and to environmental carcinogens including vinyl chloride, thorotrast, arsenic, radium, and androgenic steroids. The tumor shows a predilection for the head and neck, particularly the scalp of elderly men, where sun-damaged skin and abundant superficial vasculature may contribute. When angiosarcoma does strike the male genital system, whether at the base of the penis, the testes, the spermatic cord, or the scrotum, it is a genuine rarity, with only a handful of cases ever documented in the medical literature.

The Egyptian patient’s story began when he arrived at the surgical oncology outpatient clinic after having undergone an excisional biopsy of a scrotal lesion at another facility, where microscopic examination had already suggested angiosarcoma. He had no relevant medical or surgical history, no family history of note, and no occupational or environmental exposure to known carcinogens. On examination, clinicians found a three-centimeter residual ulcer on the right side of his scrotum, along with an atrophic testicle underneath. The absence of every classic risk factor made the diagnosis all the more puzzling, and it prompted the team to conduct a thorough diagnostic workup that combined imaging, histopathology, and immunohistochemistry.

Ultrasound of the scrotum revealed a well-defined, heterogeneous oval mass in the right hemiscrotum measuring 46 by 43 by 38 millimeters, clearly separable from the testicle, which itself appeared normal in size and echogenicity. Post-contrast magnetic resonance imaging added crucial detail: the right testicle was small with an irregular outline and showed signal characteristics consistent with infarction, meaning it had lost its blood supply, while the scrotal wall displayed diffuse thickening and enhancement suggestive of post-operative or inflammatory change. Enlarged right inguinal lymph nodes were also identified, though computed tomography of the chest, abdomen, and pelvis found no evidence of distant metastasis, a critical finding for staging and treatment planning.

The definitive diagnosis, however, rested on the microscope. Pathologists at Mansoura University revised the original biopsy slides and paraffin blocks and found malignant tumor tissue arranged in variable-sized sheets, with multiple vascular spaces lined by large, atypical cells showing moderate nuclear atypia and prominent nucleoli. Wide areas of necrosis were present, and mitotic figures, including atypical forms, were frequent, all hallmarks of a high-grade malignancy. The tumor displayed the classic architectural pattern of angiosarcoma: a proliferation of anastomosing, small, immature blood-filled spaces, with some focal solid areas, lined by plump endothelial cells set in a fibromyxoid stroma.

Immunohistochemistry, the technique that uses antibodies to detect specific proteins in tissue sections, sealed the diagnosis. The tumor cells showed diffuse, strong immunoreactivity for ERG, a transcription factor regarded as a sensitive marker of vascular endothelial differentiation, and focal positivity for CD31, another endothelial marker. The proliferation index, measured by Ki-67 staining, was strikingly high, with 60 to 70 percent of tumor cells staining positive, indicating rapid cell division. Just as important were the negative results: the tumor did not react to stains for cytokeratin, CD34, desmin, S100, smooth muscle actin, or human herpesvirus 8, which helped exclude carcinomas, other sarcoma subtypes, melanoma, and Kaposi sarcoma from consideration. Together, the morphology and immunoprofile confirmed cutaneous angiosarcoma of the scrotum.

Management was decided at a multidisciplinary sarcoma meeting, where the team opted for wide local excision. The patient underwent removal of the right hemiscrotum, including the atrophied right testicle, through a scrotal approach, and was discharged the following day. Post-operative pathology delivered welcome news: no residual tumor tissue was found in the specimen. Over eleven months of follow-up, with regular three-monthly visits involving clinical examination, basic laboratory tests, and chest imaging, the patient has shown no local recurrence and no distant metastasis, an outcome that stands in contrast to the generally dismal prognosis associated with cutaneous angiosarcoma.

The case is remarkable from several angles at once. Scrotal tumors are far more likely to be squamous cell carcinomas than angiosarcomas. Cutaneous angiosarcoma itself rarely presents in the genital skin. De novo angiosarcoma, arising without lymphedema, radiation, or a genetic syndrome, is exceedingly uncommon anywhere in the body. And this patient represents only the fifth reported case of cutaneous scrotal angiosarcoma in the literature, with previous cases having been tied to identifiable factors such as neurofibromatosis or prior radiation therapy for other cancers. The authors speculate that an unknown risk factor, perhaps a genetic predisposition or an environmental exposure not yet recognized, may underlie this tumor, opening a line of inquiry for future research.

The broader lesson for clinical practice is one of vigilance. Scrotal lesions are common in everyday practice and can range from benign cysts and inflammatory conditions to hemangiomas, lymphangiomas, and malignant tumors, so distinguishing benign from malignant disease is paramount for proper treatment. Because cutaneous angiosarcoma follows an aggressive course with early metastatic potential, and because surgery remains the only modality associated with improved survival, according to a large analysis of 764 patients, delayed diagnosis can be fatal. The Mansoura team argues that any suspicious cutaneous manifestation on the scrotum should prompt consideration of angiosarcoma, even in patients with no risk factors whatsoever. They also call for improved diagnostic criteria, standardized treatment protocols, and studies of adjuvant options such as immunotherapy and targeted therapy, along with long-term follow-up research to clarify recurrence patterns and optimize surveillance. For now, this single unusual case serves as a reminder that in oncology, rarity is not the same as impossibility, and that the rarest presentations often teach the most enduring lessons.

Subject of Research: A rare case of primary cutaneous angiosarcoma of the scrotum arising without identifiable risk factors

Article Title: Primary cutaneous scrotal angiosarcoma: a case report and literature review

Article References: Hamdy, O., Ragab, D., Farouk, B., Allam, M. M., Asy, R. A., Saleh, G. A., & Mohamed, M. A. (2024). Primary cutaneous scrotal angiosarcoma: a case report and literature review. Clinical Cancer Bulletin, 3(1), Article 20. https://doi.org/10.1007/s44272-024-00025-9

Image Credits: AI Generated

DOI: 10.1007/s44272-024-00025-9

Keywords: angiosarcoma, scrotal tumor, cutaneous angiosarcoma, case report, immunohistochemistry, ERG, CD31, sarcoma, vascular tumor, surgical oncology, rare cancer, Mansoura University

The research, led by Kwonho Hong of Konkuk University in Seoul together with an international team spanning institutions in Korea, China, and the United States, focused on a deceptively simple question: how do transcription factors gain access to the DNA they need to control during the critical window of lymphatic development? Transcription factors are the proteins that bind specific DNA sequences and switch genes on or off, but they can only reach their targets when the genome’s packaging material, chromatin, is open and accessible. The study reveals that INO80, a large molecular machine that slides and repositions nucleosomes, is what keeps those access points properly configured in lymphatic endothelial cells.

Using chromatin accessibility profiling in embryonic lymphatic endothelial cells, the team mapped the landscape of open chromatin between embryonic days 10.5 and 12.5, a period when the lymphatic vasculature is being established. They found a striking increase in accessibility at regulatory motifs for ETS family transcription factors, a group of well-known drivers of endothelial identity, and for YY1, a versatile transcriptional regulator that also happens to be a component of the INO80 complex itself. This temporal opening of the genome suggested that the cell was actively preparing its regulatory elements to receive developmental instructions, and that INO80 was positioned at the heart of that preparation.

To test whether INO80 was merely present or genuinely essential, the researchers deleted the Ino80 gene specifically in endothelial cells of mouse embryos. The result was catastrophic for the developing lymphatic system. Animals lacking INO80 in their endothelium displayed lethal lymphatic defects, including dermal edema, a swelling of the skin caused by fluid that the compromised lymphatic vessels could no longer drain. The lymphatic vessels of mutant embryos filled with blood, a hallmark phenotype of defective lymphatic-venous separation, and the lymphatic networks of the heart and mesentery were hypoplastic, meaning they failed to grow to their proper size and complexity.

At the molecular level, the consequences of INO80 loss were equally dramatic. Gene expression analysis revealed widespread dysregulation of genes controlling cell adhesion, cell migration, and vessel formation, the very processes that lymphatic endothelial cells must execute with precision to build a functional vascular network. The finding underscores a principle increasingly recognized in developmental biology: transcription factors alone are not sufficient to run a differentiation program. Without the chromatin remodeling machinery that maintains the correct accessibility landscape, even the right transcription factors cannot execute the right instructions at the right time.

The study went further, asking where INO80 actually sits in the genome of developing lymphatic endothelial cells. Mapping INO80-bound regions revealed a strong enrichment for ETS transcription factor motifs, and these occupied sites were preferentially associated with endothelial developmental genes. This genomic colocalization pointed to a functional partnership: INO80 does not act randomly across the genome but concentrates at regulatory elements where ETS factors operate, effectively shaping the chromatin terrain on which those factors depend.

One of the most intriguing discoveries involved the transcription factor ERG, an ETS family member with established roles in endothelial biology. The researchers observed that INO80 peaks containing ERG motifs were preferentially linked to angiogenic genes, genes that drive blood vessel growth, and that these same genes became dysregulated after INO80 loss. The data suggest a model in which INO80 and ERG collaborate to restrain aberrant angiogenic gene expression in lymphatic endothelial cells. In other words, INO80 is not simply an activator of the lymphatic program; it also appears to act as a gatekeeper, preventing lymphatic vessels from inappropriately adopting blood vessel-like behaviors during development.

This dual role, enabling lymphatic identity while suppressing inappropriate angiogenic programs, offers a fresh perspective on how chromatin remodelers contribute to cell fate decisions. The INO80 complex, first characterized in yeast as a regulator of nucleosome positioning and DNA repair, has emerged in vertebrates as a versatile player in transcriptional control. The new findings place it squarely within the epigenetic toolkit that lymphatic endothelial cells use to navigate their differentiation journey, alongside better-studied regulators such as the master lymphatic transcription factor PROX1 and the vascular ETS factors.

The clinical implications are potentially far-reaching. Lymphedema affects hundreds of millions of people worldwide, and congenital lymphatic malformations often trace back to defects in the same developmental pathways explored in this study. If INO80-mediated chromatin remodeling proves to be a conserved requirement for lymphatic specification in humans, it could open new avenues for understanding inherited lymphatic disorders and for designing regenerative strategies that coax lymphatic endothelial cells into forming functional vessels. Chromatin remodelers are also increasingly pursued as drug targets in oncology, and lymphatic vessels are a known route for cancer metastasis, adding another layer of therapeutic relevance.

For now, the study stands as a compelling demonstration that the three-dimensional accessibility of the genome is not a passive backdrop but an active, dynamically regulated feature of lymphatic development. By showing that INO80 shapes chromatin accessibility at ETS transcription factor-associated regulatory elements, the researchers have connected the epigenetic machinery to the transcriptional programs that build the lymphatic system, and they have revealed what happens when that connection breaks. As the field moves toward a complete mechanistic map of lymphatic vascular development, INO80 now occupies a prominent place on that map, a molecular architect whose work, though invisible to the naked eye, determines whether the body’s drainage network forms at all.

Subject of Research: INO80 chromatin remodeling in ETS transcription factor-mediated gene regulation during lymphatic endothelial cell development

Article Title: INO80 function in ETS transcription factor-mediated transcriptional programs in developing lymphatic endothelial cells

Article References: La, H., Yoo, H., Kwon, O., Thang, N. X., Moon, E.-H., Choi, D. Y., Park, C., Han, D. W., Lee, Y. J., Do, J. T., Lee, M. R., Song, H., Rhee, S., Hong, Y.-K., Jang, Y.-J., Choi, Y., & Hong, K. (2026). INO80 function in ETS transcription factor-mediated transcriptional programs in developing lymphatic endothelial cells. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06460-2

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06460-2

Keywords: INO80, lymphatic endothelial cells, chromatin remodeling, ETS transcription factors, ERG, YY1, lymphatic development, chromatin accessibility, epigenetics, gene regulation, angiogenesis, lymphedema